XOMA Corporation

NasdaqGM XOMA

XOMA Corporation EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2024

XOMA Corporation EBITDA Margin is NA for the Trailing 12 Months (TTM) ending September 30, 2024. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

XOMA Corporation EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was 46.38%.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

NasdaqGM: XOMA

XOMA Corporation

CEO	Mr. Owen P. Hughes Jr.
IPO Date	June 6, 1986
Location	United States
Headquarters	2200 Powell Street
Employees	13
Sector	Healthcare
Industries Biotechnology Pharmaceuticals

Description

XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

Key trends

Past 5 years